|1.||Verleye, Marc: 6 articles (06/2011 - 10/2002)|
|2.||Gillardin, Jean-Marie: 5 articles (06/2011 - 09/2006)|
|3.||Heulard, Isabelle: 3 articles (06/2011 - 05/2008)|
|4.||Poisbeau, Pierrick: 2 articles (02/2014 - 12/2009)|
|5.||Aouad, Maya: 2 articles (02/2014 - 12/2009)|
|6.||Blin, O: 2 articles (04/2006 - 06/2001)|
|7.||Micallef, J: 2 articles (04/2006 - 06/2001)|
|8.||Alquier, C: 2 articles (04/2006 - 06/2001)|
|9.||Choi, Yun Mi: 1 article (01/2015)|
|10.||Stein, Dan J: 1 article (01/2015)|
01/01/1985 - "Hence, etifoxine blocked both tonic and clonic seizures but was more potent against the tonic component. "
06/01/2011 - "Differential effects of etifoxine on anxiety-like behaviour and convulsions in BALB/cByJ and C57BL/6J mice: any relation to overexpression of central GABAA receptor beta2 subunits?"
06/01/2011 - "To address this issue, the experimental design of this study utilized the GABAergic compound etifoxine (with a preferential effectiveness after binding to a specific site at β(2)/β(3) subunits) tested in two inbred mouse strains: BALB/cByJ and C57BL/6J mice using three behavioural paradigms (light/dark box, elevated plus maze and restraint stress-induced small intestinal transit inhibition) and the t-butylbicyclophosphorothionate-induced convulsions model. "
10/19/1999 - "In vivo studies demonstrated an anticonvulsant effect of etifoxine (50 and 75 mg/kg, i.p.) against the clonic convulsions induced by TBPS in CD1 mice. "
01/01/1985 - "However, in terms of potency, protective indices (ED50 rotarod/ED50 seizure test) and therapeutic indices (LD50/ED50 seizure test) etifoxine was on an average 3.7, 12 and 14 times superior to valproate, respectively. "
|2.||Adjustment Disorders (Adjustment Disorder)
11/01/1998 - "These results show the interest of using etifoxine in the treatment of adjustment disorder with anxiety and should be confirmed by further studies."
11/01/1998 - "[Treatment of adjustment disorder with anxiety: efficacy and tolerance of etifoxine in a double-blind controlled study]."
01/01/2015 - "This randomized controlled trial provides support for the efficacy and safety of etifoxine in the management of adjustment disorder with anxiety, particularly when treatment discontinuation data are also assessed. "
04/01/2006 - "Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice."
01/01/2015 - "Etifoxine versus alprazolam for the treatment of adjustment disorder with anxiety: a randomized controlled trial."
|3.||Wounds and Injuries (Trauma)
02/01/2014 - "Because EFX is already distributed in several countries under the trade name of Stresam for its anxiolytic actions in humans, new clinical trials are now required to further extend its therapeutic indications as pain killer. "
01/01/2015 - "Etifoxine for pain patients with anxiety."
02/01/2014 - "In this study, we used the non-benzodiazepine anxiolytic etifoxine (EFX) to characterize its interest as pain killer and spinal mechanisms of action. "
02/01/2014 - "Using a monoarthritic rat model of pain, we tried to potentiate neural inhibition by using etifoxine (EFX), a nonbenzodiazepine anxiolytic that acts as an allosteric-positive modulator of gamma-aminobutyric acid type A (GABAA) receptor function. "
12/15/2009 - "Etifoxine (Stresam) for chemotherapy-induced pain?"
|5.||GABA-A Receptors (GABA(A) Receptor)
|7.||Neurotransmitter Agents (Neurotransmitter)
|10.||Valproic Acid (Valproate, Semisodium)
|1.||Drug Therapy (Chemotherapy)